Breaking News
Investing Pro 0
Black Friday SALE: Up to 50% OFF InvestingPro+ CLAIM OFFER

Rite Aid Plunges Following Earnings Miss as Consumer Pressure Weighs

Stock Markets Sep 29, 2022 14:20
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
RAD
-1.79%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Sam Boughedda

Rite Aid (NYSE:RAD) shares plunged over 27% Thursday after the company reported earnings before the open, missing earnings expectations.

The company reported a second-quarter loss per share of $0.63, $0.13 worse than the analyst estimate of a loss of $0.50 per share, while revenue for the quarter came in at $5.9 billion versus the consensus estimate of $5.77 billion.

Looking ahead, Rite Aid sees its fiscal 2023 loss per share coming in between $1.52 to $0.97, versus the consensus of a loss per share of $1.39. Revenue for the period is expected to be between $23.6 billion and $24 billion, versus the consensus of $23.36 billion.

Following the earnings release, JPMorgan said the company's FY23 adjusted EBITDA guidance was reduced due to continued consumer pressure and supply chain challenges.

"This morning, RAD reported F2Q23 adjusted EBITDA of $78.5M, below our $116.9M estimate and Bloomberg consensus of $107M. Adjusted EPS of -$0.63 came in below our estimate of -$0.46 and Bloomberg consensus of -$0.50. Adjusted EBITDA of $31.5M came in -54.5% below our estimates for the Retail Pharmacy while Pharmacy Services segment saw adjusted EBITDA of $47.5m, exceeding our estimate of $35.9M. The company cited prescription growth and market share, improving operating margins at Elixir along with reductions in SG&A as relevant drivers to the quarter’s performance," wrote analysts.

"The company affirmed FY23 revenue guidance while reducing adjusted EBITDA guidance to $450M-$490M, which compares with our estimate of $480M and Bloomberg consensus of $458M, and down vs. $505M in FY22. In reducing guidance, the company indicated that it expects continued pressure on consumer spending and supply chain challenges, with continued strong performance at Elixir and further SG&A expense mitigating some headwind," they added.

Meanwhile, Evercore ISI told investors in a note that Rite-Aid revenues held up reasonably well in the quarter, beating expectations.

"However, Retail EBITDA collapsed (down >50% qoq) given a 50 bps qoq (160 bps yoy) decline in gross margin and a 1.7% increase in SG&A/store (deleveraging in a high fixed cost industry is ugly). RAD did 875K COVID tests in the Q (~$17.5 MM of EBITDA out of $31.5 MM Retail EBITDA) and sold >3 MM antigen tests, raising questions about core profitability going forward. Pharmacy Services EBITDA beat expectations, almost doubling qoq," they added.

Rite Aid Plunges Following Earnings Miss as Consumer Pressure Weighs
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email